A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation.
about
Pharmacogenetics of antipsychotic adverse effects: Case studies and a literature review for cliniciansSignificant Effect of Valproate Augmentation Therapy in Patients With Schizophrenia: A Meta-analysis StudyPharmacotherapy of bipolar disorder in children and adolescents: an updatePrevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatmentPrevious hospital admissions and disease severity predict the use of antipsychotic combination treatment in patients with schizophreniaAllopurinol as adjuvant therapy in poorly responsive or treatment refractory schizophrenia.Drug information update. Unconventional treatment strategies for schizophrenia: polypharmacy and heroic dosing.Valproate for schizophrenia.Antipsychotic Polypharmacy in Clozapine Resistant Schizophrenia: A Randomized Controlled Trial of Tapering Antipsychotic Co-treatment.Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort studyAntipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behaviorValidation of a claims-based antipsychotic polypharmacy measureEmerging empirical evidence on the ethics of schizophrenia research.The Effect of Carnitine Supplementation on Hyperammonemia and Carnitine Deficiency Treated with Valproic Acid in a Psychiatric Setting.Antipsychotics prescribing patterns of patients with schizophrenia admitted to korean general hospital psychiatric unit: 2001 to 2008.Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?Adding or switching antipsychotic medications in treatment-refractory schizophrenia.Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns.Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practiceAntipsychotic polypharmacy: a Japanese survey of prescribers' attitudes and rationales.Off-licence prescribing and regulation in psychiatry: current challenges require a new model of governance.Supra-therapeutic plasma concentrations of haloperidol induce moderate inhibition of lipopolysaccharide-induced interleukin-8 release in human monocytes.Ecological Assessment of Clinicians' Antipsychotic Prescription Habits in Psychiatric Inpatients: A Novel Web- and Mobile Phone-Based Prototype for a Dynamic Clinical Decision Support SystemTreating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy.Burden of illness of people with persistent symptoms of schizophrenia: A multinational cross-sectional study.Aripiprazole augmentation of clozapine: in refractory schizophreniaGabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study.Physical comorbidity and its relevance on mortality in schizophrenia: a naturalistic 12-year follow-up in general hospital admissions.Reducing antipsychotic polypharmacy among psychogeriatric and adult patients with chronic schizophrenia.Prescription patterns for patients with schizophrenia in Korea: a focus on antipsychotic polypharmacy.Association of antipsychotic polypharmacy with health service cost: a register-based cost analysis.The prescribing pattern of a new antipsychotic: a descriptive study of aripiprazole for psychiatric in-patients.Antipsychotic medication utilization trends among Texas veterans: 1997-2002.A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia.Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy.Characteristics of Medicaid Recipients Receiving Persistent Antipsychotic Polypharmacy.Lithium response viewed as a biomarker to predict developmental psychopathology in offspring with bipolar disorder: a commentary.Effects of polypharmacy on outcome in patients with schizophrenia in routine psychiatric treatment.Deconstructing violence as a medical syndrome: mapping psychotic, impulsive, and predatory subtypes to malfunctioning brain circuits.
P2860
Q24657338-3C9A9432-F9DB-4FF6-9A0B-D4022103263AQ26772965-9D099570-F550-449C-8C04-46BC8E72B1C4Q27027052-52DD1AF8-1545-4D4C-8F60-DA3FD5F8BAA6Q27028197-56CDBA25-751F-42E8-BEE4-84DD0422A844Q31029201-500D820A-AAF0-4186-A6F5-695A1502BE37Q33264264-B0E16BD2-E8A3-46D9-AEC0-14F9907F7BB1Q33747710-155EA105-4280-4B1B-8E71-1BAE80D0A4EFQ34545761-13ECC590-E16E-4A92-B671-51C9F639F148Q34618937-DEA9A407-E0EF-4308-BECE-9A878DA056F0Q35030003-1563F7E1-ACB7-4EF6-9AA3-B462E9FFB1D0Q35175610-A4B374E3-BD5F-4903-B5F4-779DC4EE1A0EQ35801221-9D8F58E2-52A0-48D4-95EB-F743C517C1A1Q36291530-8547238A-6FFB-4BE1-8D08-B02BECEFC13DQ36307063-5CD25A70-971A-4BF7-B930-0D9804E3B9D6Q36599207-48BCD679-34DA-4497-9852-BF6C3E07FDC4Q36715888-780DDCB1-C6F2-4BD5-83A8-750BB8EF69D6Q36905070-052C224D-8672-4A5E-9932-0C80D9A8620BQ36905083-6E47BB65-D9F6-4539-B633-70C05D95193BQ37029622-E7CF860A-0698-4865-B3CB-33DA95160C32Q37216848-900A7F0C-561F-4754-9781-FD9E87CB5FCDQ37248061-10A8A9CA-C1BD-4B42-A3B1-A9AC27DF2AD4Q37410987-BDB30254-0202-4437-9AEE-2CBF50E220DBQ37634839-29737A80-DEA7-4CB2-BFAE-8A6385564B71Q38239613-2768A90C-2D3F-4218-9294-2408963D7538Q38992595-DA3593F1-3E14-4B0B-974B-A81B4437DF66Q41248446-7D07ADD0-3B8B-4B75-8722-38E210B840EFQ41732419-1AB07938-66F1-46EE-809E-845FEA7CE8E6Q42251217-A65625F9-5F04-4FC3-882B-40BA2358AC06Q42835527-DE87E593-B0B3-4924-8301-F3CA5C2D3273Q42860052-5ECDA83D-B860-4737-8196-C8F3B7CC373DQ43679387-9A732C40-6654-4E06-B4E7-1D47AB6A1DF7Q44243570-564FCCF8-4984-4146-B707-970F362411E6Q45331792-D82585C1-CE78-49CC-90E7-C3B0ECE86CFEQ46164408-F080BF0F-B59F-4B1E-967B-A07F4F8E6505Q46533468-76982EB1-6025-4138-9F17-7E1D7CC89C5AQ46901295-711E4F97-FF8F-480C-AE85-D62B064517AAQ48321579-BF5D4665-1483-467A-942B-8B6D8EF1C399Q48406708-2167EC0E-8780-47B4-834C-B03E8D022B28Q48484923-2BE590A6-FFA2-4D5D-A03F-D90CCFB9EE06Q48492684-E294A5D7-8FEF-4902-9E48-CE5B330AD130
P2860
A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation.
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
A critical review of atypical ...... polypharmacy and augmentation.
@ast
A critical review of atypical ...... polypharmacy and augmentation.
@en
A critical review of atypical ...... polypharmacy and augmentation.
@nl
type
label
A critical review of atypical ...... polypharmacy and augmentation.
@ast
A critical review of atypical ...... polypharmacy and augmentation.
@en
A critical review of atypical ...... polypharmacy and augmentation.
@nl
prefLabel
A critical review of atypical ...... polypharmacy and augmentation.
@ast
A critical review of atypical ...... polypharmacy and augmentation.
@en
A critical review of atypical ...... polypharmacy and augmentation.
@nl
P356
P1476
A critical review of atypical ...... polypharmacy and augmentation.
@en
P2093
P304
P356
10.2174/0929867043456070
P577
2004-02-01T00:00:00Z